Editorial

• Volume 2 Number 3 July-September 2009

Special reports

• i-Base Q&A: swine flu and HIV

• Swine flu pandemic

Conference reports

• 5th IAS Conference On HIV Pathogenesis, Treatment And Prevention, 19-23 July 2009, Cape Town

• Five-year survival rates of 87% without routine CD4 or laboratory monitoring in DART study demonstrate an important model for ARV access programmes

• Reducing HIV transmission during breastfeeding

• PEPI Malawi: transmission rates by maternal CD4 count

• Low transmission rates and favourable pregnancy outcomes reported in DREAM

• Pregnancy rates and outcomes among women in the DART trial

• Pregnancy outcomes in HAART exposed infants in Johannesburg

• Efavirenz conceptions in Soweto

• Impact of regimen and duration of therapy on risk of mother-to-child HIV transmission in Johannesburg

• A cost-effectiveness analysis of the OCTANE trial

• Pharmacokinetics of atazanavir/ritonavir during pregnancy

• The PEARL study

• Presentation with late stage HIV in women diagnosed during pregnancy

• Overview of TB-related studies at IAS

• Biomarkers associated with mortality: long-term follow up from SMART

• Influenza vaccine effective in HIV-positive adults

• Time from seroconversion to treatment in Europe and Africa

• Results from HSV-2 acyclovir studies

• 10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam

• Interactions between ARVs and antimalarials atovaquone and proguanil

• Efavirenz-related studies: genetics, smoking and TDM

• Atazanavir: a suitable case for TDM?

• A CYP2B6 haplotype influences nevirapine plasma concentrations following a single dose to reduce mother to child transmission

• Population pharmacokinetic model of nevirapine maternal to infant transfer through breastfeeding

• Phenotypic and genotypic inhibitory quotients and virologic response in treatment experienced children

• Tenofovir pharmacokinetics in three tenofovir-containing regimens in children and adolescents

• Bioavailability of Thai generic lopinavir/ritonavir

Treatment access

• AIDS medicine prices in the South African public and private sectors

• TMC207 open label trial for MDR-TB

• FDA approval of generic ARVs

Basic science

• Tracing HIV reservoirs

• The role of Ad5-specific CD4 T-cells in enhancing risk of HIV acquisition in the Merck vaccine trial

• Immune surveillance below the radar: study offers explanation for acyclovir’s failure to reduce HIV risk

• Maximum suppression: ART intensification does not reduce residual viral load

• Illuminating early events in HIV infection using single genome amplification

PDFs

• Volume 2 Number 3 July-September 2009 PDF